Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Monopar Therapeutics Inc.NASDAQ: MNPR
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 32.3% from a year ago
Cash & equivalents stood at $52.54M at the end of Q1 FY2026, up 32.3% from a year earlier and down 15.0% from the prior quarter. Over 3 fiscal years it compounded at +96.2% a year.
Context
- Cash & equivalents amounted to 38.1% of total assets at the end of Q1 FY2026, down 34.0 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +32.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 61.83M USD
- Year-over-year change
- +35.0%
- 4-year CAGR
- +32.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 61.83M | +35.0% |
| FY2024 | 2024-12-31 | 45.82M | +530.6% |
| FY2023 | 2023-12-31 | 7.27M | -11.2% |
| FY2022 | 2022-12-31 | 8.19M | -59.7% |
| FY2021 | 2021-12-31 | 20.3M | — |
Cash & Equivalents vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +32.3% is the 4th highest of 11, against a peer median of -10.7%.
- Cash & equivalents amounts to 38.1% of total assets for MNPR, versus a peer median of 36.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $559.47M USD | -29.4% | +22.8% | 85.8% | |
| Mar 2026 | $231.01M USD | +18.6% | -7.1% | 79.2% | |
| Sep 2026 | $212.84M USD | -21.9% | +218.0% | 42.1% | |
| Sep 2026 | $100.46M USD | +55.0% | -53.2% | 8.5% | |
| Mar 2026 | $66.52M USD | -54.3% | -19.3% | 30.5% | |
| Mar 2026 | $55.17M USD | +34.4% | -4.3% | 26.9% | |
| Mar 2026 | $52.54M USD | +32.3% | +96.2% | 38.1% | |
| Jun 2026 | $44.66M USD | +0.5% | +0.1% | 6.2% | |
| Jun 2026 | $36.47M USD | -39.1% | -23.9% | 90.8% | |
| Mar 2026 | $32.28M USD | +56.6% | -30.5% | 18.1% | |
| Dec 2025 | €28.08M EUR | -57.7% | -30.7% | 44.8% | |
| Peer median (excluding MNPR) | — | -10.7% | -13.2% | 36.3% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.